Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

NCT06060704 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Envafolimab
DRUG: Trifluridine/Tipiracil
DRUG: Bevacizumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University